<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03650933</url>
  </required_header>
  <id_info>
    <org_study_id>GB241NHL3</org_study_id>
    <nct_id>NCT03650933</nct_id>
  </id_info>
  <brief_title>A Study Comparing the Efficacy and Safety of G-CHOP Versus R-CHOP in Untreated Diffuse Large B-cell Lymphoma Patients</brief_title>
  <official_title>A Multi-center, Randomized, Double-blind, Controlled, and Parallel Phase III Study to Compare the Efficacy and Safety of GB241 (Recombinant Anti-CD20 Human-Mouse Chimeric Monoclonal Antibody Injection, Experimental Drug) Plus CHOP Versus Rituximab Plus CHOP in Untreated Diffuse Large B-cell Lymphoma (DLBCL) Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nanjing Yoko Biomedical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nanjing Yoko Biomedical Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Multi-center, Randomized, Double-blind, Controlled, and Parallel Phase III Study to Compare&#xD;
      the Efficacy and Safety of GB241 (Recombinant Anti-CD20 Human-Mouse Chimeric Monoclonal&#xD;
      Antibody Injection, Experimental Drug) Plus CHOP Versus Rituximab Plus CHOP in Untreated&#xD;
      Diffuse Large B-cell Lymphoma (DLBCL) Patients&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date type="Anticipated">October 2018</start_date>
  <completion_date type="Anticipated">October 2021</completion_date>
  <primary_completion_date type="Anticipated">October 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>6 cycles(each cycle is 3 weeks)</time_frame>
    <description>To evaluate the objective response rate (ORR) in patients with previously untreated Diffuse Large B-cell Lymphoma after six cycles of treatment.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">360</enrollment>
  <condition>Diffuse Large B-Cell Lymphoma, Unspecified Site</condition>
  <arm_group>
    <arm_group_label>G-CHOP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GB241 plus CHOP, six cycles. GB241: 375 mg/m2, IV, day 1 of each cycle; Cyclophosphamide: 750 mg/m2, IV, day 2 of each cycle; Doxorubicin: 50 mg/m2, IV, day 2 of each cycle; Vincristine: 1.4 mg/m2, up to a maximal dose of 2 mg, IV, day 2 of each cycle; Prednisone: 100 mg, po, day 2 to day 6 of each cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>R-CHOP</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Rituximab plus CHOP, six cycles. Rituximab: 375 mg/m2, IV, day 1 of each cycle; Cyclophosphamide: 750 mg/m2, IV, day 2 of each cycle; Doxorubicin: 50 mg/m2, IV, day 2 of each cycle; Vincristine: 1.4 mg/m2, up to a maximal dose of 2 mg, IV, day 2 of each cycle; Prednisone: 100 mg, po, day 2 to day 6 of each cycle.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>G-CHOP</intervention_name>
    <description>6 cycles(each cycle is 3 weeks)</description>
    <arm_group_label>G-CHOP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>R-CHOP</intervention_name>
    <description>6 cycles(each cycle is 3 weeks)</description>
    <arm_group_label>R-CHOP</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Previously untreated CD20 Positive DLBCL.&#xD;
&#xD;
          2. International Prognostic Index (IPI) score of 0 to 2, Eastern Cooperative Oncology&#xD;
             Group (ECOG) performance status of 0 to 2.&#xD;
&#xD;
          3. 18 years to 70 years; Male or female patients; Body Mass Index (BMI)≤2.13 m^2.&#xD;
&#xD;
          4. Expected survival more than 6 months.&#xD;
&#xD;
          5. At least 1 bi-dimensionally measurable lesion: Nodal lesion: Greatest transverse&#xD;
             diameter≥1.5cm and short axis≥1.0cm; Extra-nodal lesion: Greatest transverse&#xD;
             diameter≥1.0cm.&#xD;
&#xD;
          6. Cardiac echocardiography: LVEF≥50%.&#xD;
&#xD;
          7. Adequate hematological function: WBC≥3 x 10^9/L, HGB≥80g/L, ANC≥1.5 x 10^9/L, PLT≥75 x&#xD;
             10^9/L.&#xD;
&#xD;
          8. Hepatic function: TBIL≤1.5 x ULN, ALT or AST≤2.5 x ULN, ALP≤3 x ULN if with no bone&#xD;
             marrow infiltration, Renal function: Cr≤1.5 x ULN.&#xD;
&#xD;
          9. Seronegative for HCV antibody, or HIV antibody, or hepatitis B virus surface antigen&#xD;
             (HBsAg). HBc antibody seropositive, but HBV DNA and HBsAg negative patients may&#xD;
             participle following consultation with a hepatitis expert regarding monitoring and use&#xD;
             of HBV antiviral therapy, and provided they agree to receive treatment as indicated.&#xD;
&#xD;
         10. Must agree to take effective birth control methods or are not of childbearing&#xD;
             potential. Women must agree to continue contraceptive measures within 12 months after&#xD;
             the last treatment. Men must agree to continue contraception within 3 months after the&#xD;
             treatment.&#xD;
&#xD;
         11. All patients must have signed an informed consent document.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Other types of DLBCL: primary central nervous system DLBCL, primary skin DLBCL (leg&#xD;
             type), EBV-positive DLBCL, NOS, EB virus-positive skin mucosal ulcer, chronic&#xD;
             inflammation-related DLBCL, lymphomatoid granuloma, primary Mediastinal (thymus) large&#xD;
             B-cell lymphoma, intravascular large B-cell lymphoma, ALK+ large B-cell lymphoma,&#xD;
             plasmablastic lymphoma, primary exudative lymphoma, HHV8+DLBCL, NOS, Burkitt's lymph&#xD;
             Tumor, primary testicular lymphoma。&#xD;
&#xD;
          2. Confirmed DLBCL with BCL-2 and c-MYC gene rearrangement or BCL-2, BCL-6, and c-MYC&#xD;
             gene rearrangement by FISH. B-cell lymphomas, unclassifiable, with features&#xD;
             intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma.&#xD;
&#xD;
          3. B-cell lymphoma, unclassifiable, with features intermediate between diffuse large&#xD;
             B-cell lymphoma and classical Hodgkin lymphoma.&#xD;
&#xD;
          4. Previous malignant tumor except cured cervical cancer,basal cell carcinoma and&#xD;
             squamous cell skin cancer.&#xD;
&#xD;
          5. Patients who have received therapy for non-Hodgkin's lymphoma: including chemotherapy,&#xD;
             immunotherapy; radiotherapy (excluding local radiotherapy); monoclonal antibody&#xD;
             therapy; surgical treatment (excluding biopsy);&#xD;
&#xD;
          6. Patients who received continuous treatment of corticosteroid drugs lasting for more&#xD;
             than 10 days. Prednisone with the dosage over 30mg/day; Other corticosteroid drugs&#xD;
             with equal dosage.&#xD;
&#xD;
          7. Patients who received cytotoxic drugs or anti-CD20 monoclonal antibody for other&#xD;
             diseases (such as Rheumatoid arthritis).Or received any monoclonal antibody within 3&#xD;
             months prior to the enrollment of the study.&#xD;
&#xD;
          8. Patients who participated in other clinical trials within 3 months prior to the&#xD;
             enrollment of the study.&#xD;
&#xD;
          9. Patients who received attenuated or live virus vaccine within 1 month prior to the&#xD;
             enrollment of the study.&#xD;
&#xD;
         10. Patients who received hematopoietic stimulating factors within 1 week prior to the&#xD;
             enrollment of the study.&#xD;
&#xD;
         11. Recent major surgery within 1 month.&#xD;
&#xD;
         12. Active Infectious disease or significant infections requiring intravenous antibiotic&#xD;
             therapy or hospitalization in the past 4 weeks (exception of tumor induced fever).&#xD;
&#xD;
         13. Known allergic reactions against human or murine monoclonal antibody, murine products,&#xD;
             or foreign proteins.&#xD;
&#xD;
         14. Contraindicative to any drug in CHOP.&#xD;
&#xD;
         15. Patients who have significant cardiac disease, including heart disease of grade Ⅲ of Ⅳ&#xD;
             according to the New York Heart Association(NYHA) system, or occurrence of myocardial&#xD;
             infarction, unstable arrhythmia, unstable angina or severe hypertension in the past 6&#xD;
             months or peripheral nervous system(PNS) or CNS disease.&#xD;
&#xD;
         16. Suspected active tuberculosis patients.&#xD;
&#xD;
         17. Patients with serious peripheral nervous system or central nervous system disease.&#xD;
&#xD;
         18. Patients that researchers deem as not appropriate to enter the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Tie Xu, Master</last_name>
    <phone>86-18036618680</phone>
    <email>xutie@yoko-bio.com</email>
  </overall_contact>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>August 27, 2018</study_first_submitted>
  <study_first_submitted_qc>August 27, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 29, 2018</study_first_posted>
  <last_update_submitted>August 27, 2018</last_update_submitted>
  <last_update_submitted_qc>August 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 29, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>GB241</keyword>
  <keyword>Rituximab</keyword>
  <keyword>Diffuse Large B-cell Lymphoma</keyword>
  <keyword>Non Hodgkin's Lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

